0       0

33rd Annual North American Cystic Fibrosis Conference


W17 - W17--NT-ET: *New & Emerging Therapies to Correct the Basic Defect


Nov 1, 2019 2:15pm ‐ Nov 1, 2019 3:35pm

Description

During this session, we will explore data supporting the development of therapies to address the basic defect in CF including gene editing, mRNA read-through, and CFTR protein modulation. The session will cover CFTR therapeutic development along the entire pathway from pre-clinical technical advancements and target identification to results of Phase I, II and III clinical trials.

  • 1. Identify appropriate molecular targets for CFTR-directed therapeutics. 2. Review safety of potential new CFTR-directed therapies. 3. Critically evaluate efficacy data from CFTR modulator clinical trials.

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content
token-speaker-name image
token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content